Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics; D000911:Antibodies, Monoclonal / Q000737:chemistry; D018941:Antigens, CD19 / Q000096:biosynthesis*; D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007128:Immunoglobulin Fragments / Q000737:chemistry; D007074:Immunoglobulin G / Q000737:chemistry; D020128:Inhibitory Concentration 50; D008081:Liposomes / Q000737:chemistry / Q000378:metabolism*; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D013778:Tetrazolium Salts / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology; D013997:Time Factors; D014750:Vincristine / Q000493:pharmacokinetics*
D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D018941:Antigens, CD19; D000972:Antineoplastic Agents, Phytogenic; D007128:Immunoglobulin Fragments; D007074:Immunoglobulin G; D008081:Liposomes; D013778:Tetrazolium Salts; D013844:Thiazoles; D014750:Vincristine; D004317:Doxorubicin; C022616:thiazolyl blue